Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 32Filgrastim 18Irinotecan 15Topotecan 14Temozolomide 13Vincristine 12Peripheral Blood Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12Etoposide 12Melphalan 11fludarabine 10Carboplatin 9dinutuximab 8Isotretinoin 8Interleukin-2 8Busulfan 8humanized 3F8 anti-GD2 monoclonal antibody 7aldesleukin 7Doxorubicin 73-Iodobenzylguanidine 7sargramostim 6fludarabine phosphate 6Vorinostat 6Zoledronic Acid 5Stem Cell Transplantation 5Cisplatin 5etoposide phosphate 4Ipilimumab 4Drug Therapy 4ribociclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroblastoma × lexatumumab × Clear all
NCT00428272 2019-12-17

HGS-ETR2 to Treat Children With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
30 enrolled
CNSSarcoma

Neoplasm Metastasis, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡